Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma

ClinicalTrials.gov ID: NCT00051987

Public ClinicalTrials.gov record NCT00051987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma

Study identification

NCT ID
NCT00051987
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Enrollment
175 participants

Conditions and interventions

Interventions

  • VELCADE TM (bortezomib) for Injection, or PS-341 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2002
Primary completion
Feb 29, 2004
Completion
Not listed
Last update posted
Feb 10, 2008

Started 2002

United States locations

U.S. sites
22
U.S. states
18
U.S. cities
21
Facility City State ZIP Site status
Cooper Green Hospital / Jefferson Clinic P.C. Birmingham Alabama 35233
Arizona Cancer Center Tucson Arizona 85724
Arkansas Cancer Center Pine Bluff Arkansas 71603
Alta Bates Comprehensive Cancer Center Berkley California 94704
California Cancer Center Greenbrae California 94904
USC/Norris Comprehensive Cancer Center Los Angeles California 90033
City of Hope Medical Group Pasadena California 91105
H. Lee Moffit Cancer Center Tampa Florida 33612
Rush Cancer Institute Chicago Illinois 60612
Kentuckiana Cancer Institute, PLLC Louisville Kentucky 40202
West Michigan Regional Cancer and Blood Center Ludington Michigan 49431
Bond Clinic Inc. Rolla Missouri 65402
Nevada Cancer Center Las Vegas Nevada 89109
Norris Cotton Cancer Center Lebanon New Hampshire 03756
The Cancer Institute of New Jersey New Brunswick New Jersey 08901
New York University New York New York 10016
St. Lukes Rossevelt Hospital New York New York 10019
UNC School of Medicine Chapel Hill North Carolina 27599
Ohio State University Medical Center Columbus Ohio 43210
Oregon Health Sciences Portland Oregon 97201
Memphis Cancer Center, PC Memphis Tennessee 38119
University of Texas Health Sciences Center at San Antonio San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00051987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2008 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00051987 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →